«Back to Press Releases
May 29, 2012
Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals related to Lidoderm® - Agreement protects Lidoderm® and eliminates uncertainty
Endo (Nasdaq: ENDP) announced on May 29, 2012 that it reached a settlement with Watson Pharmaceuticals (Watson) which resolved two patent infringement lawsuits related to Lidoderm®.
Endo’s President and CEO, Dave Holveck stated “We are pleased to have reached an agreement that protects Endo’s intellectual property interests and eliminates the uncertainty of a court decision.” and “We believe this agreement will benefit consumers and resolving this issue is another step forward in establishing Endo as the dynamic, diversified healthcare solutions company that we are today.”
The press release can be viewed in its’ entirety at www.endo.com/news-events
About Teikoku Pharma USA
Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd., is a leading supplier of the topical analgesic transdermal patch, Lidoderm. They are a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology. Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). The company looks forward to exploring a new field of CNS with the systemic transdermal patch. Teikoku is committed to applying its transdermal technology for the benefit of patients and partners.
Teikoku Pharma USA, Inc.